| Julie Bond, | |
|
1100 N Kentucky Ave, West Plains, MO 65775-2029 | |
| (417) 257-5959 | |
| Not Available |
| Full Name | Julie Bond |
|---|---|
| Gender | Female |
| Speciality | Physical Therapist |
| Location | 1100 N Kentucky Ave, West Plains, Missouri |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457499907 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 115875 (Missouri) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Julie Bond, Po Box 1100, West Plains, MO 65775-1100 Ph: () - | Julie Bond, 1100 N Kentucky Ave, West Plains, MO 65775-2029 Ph: (417) 257-5959 |
News Archive
As the chairman of the trade group Pharmaceutical Research and Manufacturers of America, Kindler was instrumental in lining up drugmaker support for this year's health care overhaul in a deal that ultimately will bring those companies more customers and sales. The industry had helped defeat the Clinton adminstration's attempt to reform health care in 1994
Chromogenex, a world leader in laser innovation, announced today the launch of i-LipoXcell, the company's non-surgical fat reduction and body shaping system. Representing third generation technology, i-LipoXcell incorporates both visible red and infrared lasers for bio-stimulation of metabolic pathways, effectively shrinking fat cells through the release of fatty acids and glycerol.
E-cigarette use has increased dramatically over the last decade. With its popularity, the use of e-cigarette spans from adolescents to adults. Now, cardiologists warn against the use of e-cigarettes and how these devices cause damage to vital organs, including the heart, brain, lungs, and blood vessels.
The U.S. Food and Drug Administration has approved Eli Lilly's Cymbalta, a balanced and potent serotonin and norepinephrine reuptake inhibitor. Cymbalta is the first and only FDA-approved treatment for pain caused by diabetic peripheral neuropathy.
Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it has enrolled the first patient in a U.S. Phase 2 trial evaluating NOV-205 as monotherapy in up to 40 chronic hepatitis C genotype 1 patients who previously failed treatment with pegylated interferon plus ribavirin.
› Verified 5 days ago
Logan Miller, Physical Therapist Medicare: Medicare Enrolled Practice Location: 1111 N Kentucky Ave, West Plains, MO 65775 Phone: 417-257-5959 | |
Emily Elliott, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1625 Gibson St, West Plains, MO 65775 Phone: 417-255-9577 | |
Ms. Deanna J Miller, PT, MPT, PCS Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 9068 Private Road 6421, West Plains, MO 65775 Phone: 417-543-2744 Fax: 417-256-1584 | |
Kaitlyn Baker, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1111 N Kentucky Ave, West Plains, MO 65775 Phone: 417-256-9111 | |
Paul Byrum, Physical Therapist Medicare: Medicare Enrolled Practice Location: 1480 8th St, West Plains, MO 65775 Phone: 417-256-5669 Fax: 417-256-5699 | |
Brody Paul Smith, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1111 N Kentucky Ave, West Plains, MO 65775 Phone: 417-257-5959 | |
Karla Daffron, Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1100 N Kentucky Ave, West Plains, MO 65775 Phone: 417-257-5959 |